Cost-Effectiveness of Screening for Atrial Fibrillation Using Wearable Devices
2022
This economic evaluation assesses the cost-effectiveness of atrial fibrillation (AF) screening strategies, particularly utilizing wrist-worn wearable devices, to prevent strokes. Conducted using a microsimulation decision-analytic model, the study spans from September 8, 2020, to May 23, 2022, incorporating 30 million simulated individuals representative of the US population aged 65 years or older. Eight screening strategies, including six employing wrist-worn devices and two using traditional methods, were compared against no screening. Results indicate that all wrist-worn device-based strategies were more effective than no screening, with wearable photoplethysmography being the preferred strategy at an incremental cost-effectiveness ratio of $57,894 per quality-adjusted life-year (QALY), meeting the $100,000 per QALY threshold. While screening reduced stroke incidence, it also increased major bleeding. The findings suggest that AF screening using wearable devices is cost-effective compared to traditional methods or no screening.
Cost-Effectiveness of Screening for Atrial Fibrillation Using Wearable Devices
Source:
Chen W, Khurshid S, Singer DE, Atlas SJ, Ashburner JM, Ellinor PT, McManus DD, Lubitz SA, Chhatwal J. Cost-Effectiveness of Screening for Atrial Fibrillation Using Wearable Devices. JAMA Health Forum 2022; 3 (8): e222419. https://doi.org/10.1001/jamahealthforum.2022.2419